The US Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs market size is projected to reach USD xx billion in 2019 and will reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
The US PNH treatment market is anticipated to expand at a rapid pace during the forecast period. It is a niche market, with many pharmaceutical and biotech companies investing in research of bone marrow stem cells. According to current studies, the ideal treatment available is to replace all the hematopoietic stem cells with normal stem cells via stem cells transplantation. However, this treatment is not ideal in some cases as stem cell transplantation requires a stable histocompatible donor. Complete stem cells transplantation is usually considered in severe cases of PNH, for instance aplastic anaemia and transformation to leukemia, as these can be life threatening complications. Factors driving the PNH treatment market include rise in number of blood & bone marrow related disorders, increase in aging population, and technological advancements in stem cells transplantation
Increasing prevalence of blood disorders is driving the market growth. Emergence of biologics that target causal haemolytic defect or abnormal hematopoietic stem cell is boosting the market growth in the forecast period. High unmet demand for drugs in developing countries is also driving the market growth. Rise in investment from government, public & private organizations for the development of novel drugs is acting as catalyst to market growth